Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

8.860 +0.560 (+6.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 203,171
Open 8.220
Bid (Size) 8.650 (5)
Ask (Size) 8.980 (2)
Prev. Close 8.300
Today's Range 8.220 - 8.940
52wk Range 4.320 - 12.72
Shares Outstanding 17,703,692
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire

Performance

YTD
+79.7%
+79.7%
1 Month
+10.7%
+10.7%
3 Month
+97.3%
+97.3%
6 Month
+73.0%
+73.0%
1 Year
-24.3%
-24.3%

More News

Read More
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
From INmune Bio, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
C-Suite Buy of the Week: Executive Moves from Biotech to Banking
Via Benzinga
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt
From INmune Bio, Inc.
Via GlobeNewswire
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
From OmniScience
Via Business Wire
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
From INmune Bio, Inc.
Via GlobeNewswire
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Announces $13.0 Million Registered Direct Offering
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
From INmune Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
INmune Bio Inc. to Join Russell 3000® Index
From INmune Bio, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is INmune Bio Inc. - Common stock publicly traded?
Yes, INmune Bio Inc. - Common stock is publicly traded.
What exchange does INmune Bio Inc. - Common stock trade on?
INmune Bio Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for INmune Bio Inc. - Common stock?
The ticker symbol for INmune Bio Inc. - Common stock is INMB on the Nasdaq Stock Market
What is the current price of INmune Bio Inc. - Common stock?
The current price of INmune Bio Inc. - Common stock is 8.860
When was INmune Bio Inc. - Common stock last traded?
The last trade of INmune Bio Inc. - Common stock was at 03/25/25 04:00 PM ET
What is the market capitalization of INmune Bio Inc. - Common stock?
The market capitalization of INmune Bio Inc. - Common stock is 156.85M
How many shares of INmune Bio Inc. - Common stock are outstanding?
INmune Bio Inc. - Common stock has 157M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.